Mutations selected in the hepatitis C virus NS3 protease domain during sequential treatment with boceprevir with and without pegylated interferon alfa-2b

Journal of Viral Hepatitis

Volumn 19, Issue 2, 2012, Pages 120-127

  Vermehren, J ^a   Susser, S ^a   Lange, C M ^a   Forestier, N ^a   Karey, U ^a   Hughes, E ^b   Ralston, R ^b   Tong, X ^b   Zeuzem, S ^a   Sarrazin, C ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

chronic hepatitis C; direct acting antiviral; genotypic resistance; re treatment

Indexed keywords

BOCEPREVIR; NONSTRUCTURAL PROTEIN 3; PEGINTERFERON ALPHA2B; VIRUS RNA;

ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; ANTIVIRAL THERAPY; ARTICLE; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; GENETIC VARIABILITY; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MONOTHERAPY; MUTATIONAL ANALYSIS; NONHUMAN; PRIORITY JOURNAL; SEQUENCE ALIGNMENT; SEQUENCE ANALYSIS; TREATMENT OUTCOME; TREATMENT RESPONSE; VIRUS ISOLATION; VIRUS MUTANT; VIRUS MUTATION; WILD TYPE;

AMINO ACID SUBSTITUTION; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERFERON-ALPHA; MUTATION, MISSENSE; POLYETHYLENE GLYCOLS; PROLINE; RECOMBINANT PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS, DNA; TREATMENT FAILURE; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84855860795     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2011.01449.x     Document Type: Article

References (28)

1. World Health Organization. Hepatitis C Virus. Available at: http://www.who.int/vaccine-research/diseases/viral-cancers/en/index2.html (accessed 1 December 2010).
2. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-982.
3. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-965. (Pubitemid 32913521)
4. Kwo PY, Lawitz EJ, McCone J, et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet 2010; 376: 705-716.
5. Hezode C, Forestier N, Dusheiko G, et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009; 360: 1839-1850.
6. Sarrazin C, Zeuzem S,. Resistance to direct antiviral agents in patients with hepatitis C virus infection. Gastroenterology 2010; 138: 447-462.
7. McHutchison JG, Everson GT, Gordon SC, et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009; 360: 1827-1838.
8. Kieffer TL, Sarrazin C, Miller JS, et al. Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients. Hepatology 2007; 46: 631-639. (Pubitemid 47436107)
9. Susser S, Welsch C, Wang Y, et al. Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients. Hepatology 2009; 50: 1709-1718.
10. Sarrazin C, Kieffer TL, Bartels D, et al. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology 2007; 132: 1767-1777. (Pubitemid 46677938)
11. Vierling JM, Ralston R, Lawitz EJ, et al. Long-term outcomes following combination treatment with boceprevir plus PEG-Intron/ribavirin (P/R) in patients with chronic hepatitis C, genotype 1 (CHC-G1). J Hepatol 2010; 52: S470-S471.
12. Susser S, Forestier N, Vermehren J, Grigorian N,. Decline of detectable resistance mutations within the HCV NS3 protease quasispecies during long-term follow-up after treatment with telaprevir. J Hepatol 2010; 52: S300.
13. Reesink HW, de Bruijne J, Weegink CJ, et al. Antiviral activity and safety of TMC435 combined with pegylated interferon and ribavirin in hepatitis C patients with genotype-1 who had previous exposure to TMC435. Hepatology 2009; 50: 1024A.
14. Sarrazin C, Rouzier R, Wagner F, et al. SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders. Gastroenterology 2007; 132: 1270-1278. (Pubitemid 46627577)
15. Marcellin P, Forns X, Goeser T, et al. Telaprevir is effective given every 8 or 12 hours with ribavirin and peginterferon alfa-2a or -2b to patients with chronic hepatitis C. Gastroenterology 2011; 140: 459-468.
16. Tong X, Bogen S, Chase R, et al. Characterization of resistance mutations against HCV ketoamide protease inhibitors. Antiviral Res 2008; 77: 177-185.
17. Qiu P, Sanfiorenzo V, Curry S, et al. Identification of HCV protease inhibitor resistance mutations by selection pressure-based method. Nucleic Acids Res 2009; 37: e74.
18. Bartels DJ, Zhou Y, Zhang EZ, et al. Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3.4A protease inhibitors in treatment-naive subjects. J Infect Dis 2008; 198: 800-807.
19. Colson P, Brouk N, Lembo F, Castellani P, Tamalet C, Gerolami R,. Natural presence of substitution R155K within hepatitis C virus NS3 protease from a treatment-naive chronically infected patient. Hepatology 2008; 47: 766-767. (Pubitemid 351280756)
20. Gaudieri S, Rauch A, Pfafferott K, et al. Hepatitis C virus drug resistance and immune-driven adaptations: relevance to new antiviral therapy. Hepatology 2009; 49: 1069-1082.
21. Kim AY, Timm J, Nolan BE, et al. Temporal dynamics of a predominant protease inhibitor-resistance mutation in a treatment-naive, hepatitis C virus-infected individual. J Infect Dis 2009; 199: 737-741.
22. Kuntzen T, Timm J, Berical A, et al. Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naive patients. Hepatology 2008; 48: 1769-1778.
23. Iarikov DE, Irizarry-Acosta M, Martorell C, Rauch CA, Hoffman RP, Skiest DJ,. Use of HIV resistance testing after prolonged treatment interruption. J Acquir Immune Defic Syndr 2010; 53: 333-337.
24. Reijnders JG, Deterding K, Petersen J, et al. Antiviral effect of entecavir in chronic hepatitis B: influence of prior exposure to nucleos(t)ide analogues. J Hepatol 2010; 52: 493-500.
25. Shim JH, Suh DJ, Kim KM, et al. Efficacy of entecavir in patients with chronic hepatitis B resistant to both lamivudine and adefovir or to lamivudine alone. Hepatology 2009; 50: 1064-1071.
26. Rehermann B, Nascimbeni M,. Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol 2005; 5: 215-229. (Pubitemid 40364823)
27. Turner BG, Summers MF,. Structural biology of HIV. J Mol Biol 1999; 285: 1-32. (Pubitemid 29034021)
28. Soriano V, Perelson AS, Zoulim F,. Why are there different dynamics in the selection of drug resistance in HIV and hepatitis B and C viruses? J Antimicrob Chemother 2008; 62: 1-4. (Pubitemid 351865869)